

# Antonio Cuneo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8139086/publications.pdf>

Version: 2024-02-01

130  
papers

3,338  
citations

186209

28  
h-index

168321

53  
g-index

134  
all docs

134  
docs citations

134  
times ranked

3870  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Subgroups in B-Cell Chronic Lymphocytic Leukemia Defined by Specific Chromosomal Abnormalities. <i>New England Journal of Medicine</i> , 1990, 323, 720-724.	13.9	563
2	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
3	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	0.6	197
4	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , 2019, 133, 1205-1216.	0.6	164
5	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 121-128.	0.7	133
6	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	2.0	106
7	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014, 89, 480-486.	2.0	104
8	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. <i>British Journal of Haematology</i> , 2008, 142, 529-537.	1.2	78
9	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters. <i>Blood</i> , 2012, 119, 2310-2313.	0.6	64
10	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	1.7	64
11	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 99-99.	0.6	63
12	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086.	0.8	63
13	Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. <i>Hematological Oncology</i> , 2019, 37, 3-14.	0.8	59
14	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	3.3	57
15	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	0.8	55
16	BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. <i>Blood</i> , 2017, 129, 582-586.	0.6	49
17	Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death. <i>Scientific Reports</i> , 2016, 6, 26280.	1.6	47
18	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	0.8	46

#	ARTICLE	IF	CITATIONS
19	Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents. <i>Cancer</i> , 1992, 70, 77-85.	2.0	43
20	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	2.8	41
21	Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. <i>Haematologica</i> , 2002, 87, 44-51.	1.7	39
22	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 818-826.	1.5	37
23	Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. <i>Journal of Hematology and Oncology</i> , 2016, 9, 88.	6.9	35
24	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. <i>British Journal of Haematology</i> , 2018, 181, 229-233.	1.2	34
25	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020, 136, 763-766.	0.6	33
26	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753.	2.5	33
27	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2019, 121, 150-156.	2.9	31
28	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. <i>Haematologica</i> , 2022, 107, 868-876.	1.7	31
29	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
30	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	0.6	30
31	Circulating endothelial cells in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2010, 116, 1926-1937.	2.0	29
32	Efficacy and safety of ruxolitinib in intermediate- and high-risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	0.8	29
33	Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. <i>Journal of Translational Medicine</i> , 2018, 16, 172.	1.8	24
34	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	1.8	24
35	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2014, 42, 126-136.e1.	0.2	23
36	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.4	23

#	ARTICLE	IF	CITATIONS
37	Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. <i>Oncotarget</i> , 2014, 5, 4347-4360.	0.8	22
38	Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. <i>Cancer Medicine</i> , 2014, 3, 555-564.	1.3	21
39	Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 70623-70638.	0.8	21
40	Ibrutinib in the real world patient: many lights and some shades. <i>Haematologica</i> , 2016, 101, 1448-1450.	1.7	21
41	Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. <i>Leukemia and Lymphoma</i> , 2016, 57, 2685-2688.	0.6	20
42	Trisomy 12 in Chronic Lymphocytic Leukemia and Hairy Cell Leukemia: A Cytogenetic and Interphase Cytogenetic Study. <i>Leukemia and Lymphoma</i> , 1994, 15, 167-172.	0.6	18
43	Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2022, 107, 593-603.	1.7	18
44	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	3.3	17
45	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 637186.	1.3	17
46	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	1.7	16
47	The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway. <i>Oncotarget</i> , 2015, 6, 2385-2396.	0.8	16
48	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	0.8	15
49	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	2.0	14
50	Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	14
51	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. <i>Leukemia Research</i> , 2014, 38, 1269-1277.	0.4	13
52	An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness. <i>Oncotarget</i> , 2017, 8, 28008-28020.	0.8	13
53	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 508-512.	0.8	13
54	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. <i>Haematologica</i> , 2022, 107, 1470-1473.	1.7	12
56	Clinical Review on Features and Cytogenetic Patterns in Adult Acute Myeloid Leukemia with Lymphoid Markers. <i>Leukemia and Lymphoma</i> , 1993, 9, 285-291.	0.6	11
57	Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 828-836.	0.6	11
58	Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2018, 9, 34398-34412.	0.8	11
59	Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia. <i>Tumor Biology</i> , 2017, 39, 101042831769432.	0.8	10
60	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	0.8	10
61	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	2.0	10
62	Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. <i>Oncotarget</i> , 2014, 5, 140-149.	0.8	10
63	Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case. <i>Annals of Hematology</i> , 2001, 80, 246-250.	0.8	9
64	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. <i>Haematologica</i> , 2017, 102, e352-e355.	1.7	9
65	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021, 39, 409-418.	0.8	9
66	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	0.8	9
67	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. <i>Blood</i> , 2021, 138, 2727-2730.	0.6	9
68	The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. <i>Oncotarget</i> , 2014, 5, 12635-12645.	0.8	9
69	IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia. <i>Apmis</i> , 2017, 125, 511-522.	0.9	8
70	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	0.8	8
71	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	2.0	8
72	Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2009, 2, 305-314.	1.0	7

#	ARTICLE	IF	CITATIONS
73	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 459-466.	0.4	7
74	Hsa-miR-15a and Hsa-miR-16-1 Expression Is Not Related to Proliferation Centers Abundance and Other Prognostic Factors in Chronic Lymphocytic Leukemia. <i>BioMed Research International</i> , 2013, 2013, 1-13.	0.9	7
75	The emerging role of GSK $\beta$ in the pathobiology of classical Hodgkin lymphoma. <i>Histopathology</i> , 2017, 71, 72-80.	1.6	7
76	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 423-433.	0.6	7
77	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib+rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	2.8	7
78	COVID-19 and Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 328-333.	1.0	7
79	Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. <i>Haematologica</i> , 2021, 106, 1500-1503.	1.7	7
80	Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement. <i>Annals of Hematology</i> , 2022, 101, 297-307.	0.8	7
81	IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016047.	0.5	6
82	Chronic Myeloid Leukemia Patient's Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial. <i>Frontiers in Psychology</i> , 2019, 10, 329.	1.1	6
83	RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019024.	0.5	6
84	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018, 132, 3118-3118.	0.6	6
85	Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 2076.	1.0	6
86	Cytogenetics of Hybrid Acute Leukemias. <i>Leukemia and Lymphoma</i> , 1995, 18, 19-23.	0.6	5
87	Complex chromosomal rearrangements leading to <i>MECOM</i> overexpression are recurrent in myeloid malignancies with various 3q abnormalities. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 375-388.	1.5	5
88	In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome. <i>British Journal of Haematology</i> , 2021, 192, 1068-1072.	1.2	5
89	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	1.1	5
90	MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study. <i>Blood</i> , 2012, 120, 3677-3677.	0.6	5

#	ARTICLE	IF	CITATIONS
91	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5
92	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014, 38, 198-203.	0.4	4
93	Right Atrium Mass Assessed with 18F-FDG PET/CT Scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report. <i>Diagnostics</i> , 2020, 10, 987.	1.3	4
94	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , 2020, 4, e395.	1.2	4
95	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. <i>Blood</i> , 2012, 120, 2601-2601.	0.6	4
96	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. <i>Blood</i> , 2016, 128, 1128-1128.	0.6	4
97	Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. <i>Oncology Reports</i> , 2020, 44, 1561-1573.	1.2	4
98	Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 334-337.	1.7	4
99	Dissecting chronic lymphocytic leukemia with 13q- using microRNA expression profile. <i>Leukemia Research</i> , 2016, 47, 114-115.	0.4	3
100	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	0.8	3
101	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	2.0	3
102	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. <i>Blood</i> , 2018, 132, 4303-4303.	0.6	3
103	Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter Follidela Study. <i>Cancers</i> , 2022, 14, 654.	1.7	3
104	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	1.7	3
105	A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. <i>Genes</i> , 2020, 11, 1453.	1.0	2
106	Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?. <i>Haematologica</i> , 2020, 106, 7-9.	1.7	2
107	Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 320-327.	1.0	2
108	In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1782-1782.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4174-4174.	0.6	2
110	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
111	<i>BCR/ABL1</i> -positive acute lymphoblastic leukemia relapsing as <i>BCR/ABL1</i> -negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 2065-2067.	0.6	1
112	TP53 mutations and Azacitidine treatment: To be or not to be related?. <i>Leukemia Research</i> , 2014, 38, 727-728.	0.4	1
113	Spontaneously reversible adrenal nodules in primary diffuse large B-cell testicular lymphoma mimicking an extranodal involvement: A case report. <i>Radiology Case Reports</i> , 2021, 16, 2168-2173.	0.2	1
114	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. <i>Blood</i> , 2018, 132, 2293-2293.	0.6	1
115	Chromosome Banding Analysis Versus Genomic Microarrays: A Comparison of Methods for Genomic Complexity Risk Stratification in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. <i>Blood</i> , 2019, 134, 4287-4287.	0.6	1
116	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4184-4184.	0.6	1
117	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. <i>Blood</i> , 2020, 136, 17-18.	0.6	1
118	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. <i>Blood</i> , 2020, 136, 33-34.	0.6	1
119	Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. <i>Frontiers in Oncology</i> , 2021, 11, 638689.	1.3	0
120	Heterogeneous Chromosomal Mechanisms Generating the 5â€²RUNX1/3â€²CBFA2T1 Gene in Acute Myeloid Leukemia.. <i>Blood</i> , 2004, 104, 4272-4272.	0.6	0
121	Chromosome 9 and 22 Breakpoints Cluster Regions Definition of Deleted Sequences on der(9) in Chronic Myeloid Leukemia.. <i>Blood</i> , 2005, 106, 4842-4842.	0.6	0
122	Unfavourable Outcome and Heterogeneity of Partner Chromosomes in Chronic Lymphocytic Leukemia with 14q32/IGH Translocations.. <i>Blood</i> , 2007, 110, 4686-4686.	0.6	0
123	A Prospective, Multi Center Phase II Study Evaluating Predictive Factors for Lenalidomide Treatment in Relapse or Refractory Chronic Lymphocytic Leukemia Patients (LE.P.RE.): Preliminary Results about the First 20 Enrolled Patients. <i>Blood</i> , 2011, 118, 1782-1782.	0.6	0
124	Merkel-Cell Polyomavirus Is Rarely Associated to B-Chronic Lymphocytic Leukemia and Occurs Late in the Natural History of the Disease. <i>Blood</i> , 2012, 120, 4578-4578.	0.6	0
125	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. <i>Blood</i> , 2016, 128, 3240-3240.	0.6	0
126	Una Valutazione Economica Delle Sequenze Terapeutiche nel Trattamento di Prima Linea Della Leucemia Linfatica Cronica in Pazienti Unfit non Pretrattati. <i>Global &amp; Regional Health Technology Assessment</i> , 2017, 4, grhta.5000275.	0.2	0



#	ARTICLE	IF	CITATIONS
127	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019, 134, 4166-4166.	0.6	0
128	Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. <i>Blood</i> , 2021, 138, 2641-2641.	0.6	0
129	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
130	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. <i>Blood</i> , 2020, 136, 49-50.	0.6	0